CAJ | 학술논문

目的：：探讨替比夫定治疗失代偿期乙肝肝硬化的临床疗效。方法：抽取2012年2月~2014年2月某院接诊的76例失代偿乙肝肝硬化患者为研究对象,根据抽签法随机抽取38例患者采用替比夫定的治疗,作为观察组；38例患者采用常规治疗,作为对照组。观察两组患者的肝功能指标、肝纤维化指标以及药物不良反应的情况。结果：治疗后观察组的 ALT、TBIL指标明显低于对照组,ALB指标明显高于对照组,组间比较差异具有统计学意义(P<0.05)；治疗后观察组的肝纤维化指标 CIV、PIIINP、LN 以及HA均明显低于对照组,组间差异具有统计学意义(P<0.05)；观察组总不良反应发生率5.26%明显低于对照组的26.32%,两组差异具有统计学意义(χ2=6.333,P<0.05)。结论：替比夫定治疗失代偿期乙肝肝硬化具有更好的治疗效果,能有效改善患者的肝功能并抑制病情的发展,具有一定的临床意义。
목적：：탐토체비부정치료실대상기을간간경화적림상료효。방법：추취2012년2월~2014년2월모원접진적76례실대상을간간경화환자위연구대상,근거추첨법수궤추취38례환자채용체비부정적치료,작위관찰조；38례환자채용상규치료,작위대조조。관찰량조환자적간공능지표、간섬유화지표이급약물불량반응적정황。결과：치료후관찰조적 ALT、TBIL지표명현저우대조조,ALB지표명현고우대조조,조간비교차이구유통계학의의(P<0.05)；치료후관찰조적간섬유화지표 CIV、PIIINP、LN 이급HA균명현저우대조조,조간차이구유통계학의의(P<0.05)；관찰조총불량반응발생솔5.26%명현저우대조조적26.32%,량조차이구유통계학의의(χ2=6.333,P<0.05)。결론：체비부정치료실대상기을간간경화구유경호적치료효과,능유효개선환자적간공능병억제병정적발전,구유일정적림상의의。
Objective:To investigate the clinical effect of telbivudine on Hepatitis B-related cirrhosis in de-compensatory stage.Methods:Sample 76 patients with Hepatitis B-related cirrhosis within decompensatory stage received in our hospital during the period from February 2012 to February 2014 as the research object, select 38 patients according to the random sampling method as the observation group and treat them with tel-bivudine and the other 38 patients were defined as the control group and received conventional treatment.Ob-serve the indexes of liver function ,the indexes of hepatic fibrosis and adverse drug reaction.Results:After treatment,the index of ALT and TBIL in observation group were obviously lower than that in control group, and the index of ALB was obviously higher than that in control group,the differences between the 2 groups were statistically significant(P<0.05).After treatment,CIV、PIIINP、LN and HA in observation group were all lower than that in control group ,the differences between the 2 groups were statistically significant(P<0.05).In observation group,the overall occurrence rate of adverse reaction was 5.26% ,which was lower than that in control group(26.32%),the differences between the 2 groups were statistically significant(χ2=6.333,P<0.05).Conclusion:It is more effective to treat patients with Hepatitis B-related cirrhosis within de-compensatory stage,it would effectively improve patients'liver function and inhibit the development of the situation,it is of some clinical significance.